Celemics, Inc. (KOSDAQ:331920)
South Korea · Delayed Price · Currency is KRW 10,070
+260 (2.65%)
At close: Oct 21, 2026
Celemics Revenue
Celemics had revenue of 1.38B KRW in the quarter ending June 30, 2026, with 22.38% growth. This brings the company's total for the last twelve months to 5.22B, down -16.21% year-over-year. In the year 2025, Celemics had annual revenue of 5.77B, down -14.16%. That makes Celemics the 40,688th largest company in the world by revenue and 2,510th in South Korea.
Revenue (ttm)
5.22B
Revenue Growth
-16.21%
P/S Ratio
21.57
Revenue / Employee
113.48M
Employees
46
Market Cap
112.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.77B | -951.36M | -14.16% |
| Dec 31, 2024 | 6.72B | 141.42M | 2.15% |
| Dec 31, 2023 | 6.58B | -2.15B | -24.65% |
| Dec 31, 2022 | 8.73B | 7.17B | 461.56% |
| Dec 31, 2016 | 1.55B | 812.79M | 109.60% |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Synergy Innovation | 116.56B |
| DENTIS CO.,Ltd | 111.69B |
| Corentec | 104.75B |
| M.I.TECH Co.,Ltd | 70.72B |
| BIOBIJOU | 28.56B |
| Sanigen Co. | 14.21B |
| Finemedix | 11.43B |
| Genolution | 10.03B |